Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Dr. Igor Aurer on Novel Treatments on the Horizon in Hodgkin Lymphoma

July 27th 2016

Dr. DeAngelo on Inotuzumab Ozogamicin for Relapsed/Refractory ALL

July 26th 2016

Dr. Younes Discusses FDA Approval of Nivolumab in Hodgkin Lymphoma

July 25th 2016

Anas Younes, MD, chief of the Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses the impact of the FDA approval of nivolumab (Opdivo) for the treatment of patients with classical Hodgkin lymphoma.

Where Immuno-Oncology Is Heading

July 20th 2016

Brentuximab Vedotin in Advanced Lymphoid Malignancies

July 20th 2016

Anti-CD20 Antibodies for Advanced Hematologic Malignancies

July 20th 2016

Obinutuzumab for Indolent Lymphoma

July 20th 2016

Immunochemotherapy for Lymphoma

July 20th 2016

Resistance with CAR-T Therapy

July 20th 2016

Where Does CAR-T Fit in the Context of Transplant?

July 20th 2016

Recent Trials of CAR-T Therapy

July 20th 2016

Toxicity Management for CAR-T in Hematologic Malignancies

July 20th 2016

Obstacles to Using CAR-T Therapy in Hematologic Malignancies

July 20th 2016

CAR-T Cell Therapy in Hematologic Malignancies

July 20th 2016

The Potential for Combining Checkpoint Inhibitors

July 20th 2016

Immunotherapy for Follicular Lymphoma

July 20th 2016

Immunotherapy in Refractory DLBCL

July 20th 2016

PD-1 Inhibitors in Hodgkin Lymphoma

July 20th 2016

Immunotherapy Response Among Hematologic Malignancies

July 20th 2016

Immunotherapy: What is the Role in Lymphoid Cancers?

July 20th 2016